Enlitic has landed its inaugural Australian Ensight subscription contract with Lumus Imaging, marking a strategic entry into the local SaaS market and expanding its footprint in diagnostic imaging workflows.
- Three-year Ensight subscription with Lumus Imaging
- Contract valued at US$248,000 (~A$359,000)
- Deployment across hanging protocols, deidentification, AI validation
- Leverages existing Intelerad IntelePACS integration
- Supports transition to recurring SaaS revenue model
First Australian Ensight Subscription Contract Signed
Enlitic (ASX:ENL) has secured its first Australian Ensight subscription agreement, locking in a three-year deal with Lumus Imaging, a major diagnostic imaging provider operating 150 locations nationwide. Valued at US$248,000 (approximately A$359,000), the contract marks a significant milestone as Enlitic pushes deeper into the Australian market with its AI-powered medical imaging software.
The deal covers deployment of the full Ensight platform across multiple core use cases: Hanging Protocols to standardise image presentation for radiologists, deidentification to protect patient privacy, and AI validation to ensure diagnostic accuracy. This multi-faceted adoption underscores growing demand for Ensight as a comprehensive data infrastructure solution rather than a simple migration tool.
Strategic Expansion Leveraging Existing Integrations
Lumus Imaging’s use of Intelerad’s IntelePACS platform allows Enlitic to deploy Ensight through an existing integration, first proven with New Zealand’s largest private radiology provider, RHCNZ Medical Imaging Group. This second enterprise deployment via Intelerad demonstrates the repeatability of Enlitic’s OEM channel strategy, potentially smoothing the path for further subscriptions across Australia and the broader Asia-Pacific region.
Lumus, with over 30 years in the Australian diagnostic imaging sector and a workforce exceeding 2,000 healthcare professionals, offers a broad range of modalities including MRI, CT, ultrasound, mammography, and nuclear medicine. The scale and diversity of Lumus’ operations provide a robust testbed for Ensight’s capabilities and a visible reference point for future enterprise sales.
Supporting Enlitic’s SaaS Revenue Transition
CEO Michael Sistenich highlighted the contract as a pivotal step in Enlitic’s shift from one-off migration and services revenue to a recurring SaaS model. The multi-year agreement not only delivers a steady revenue stream but also opens avenues for expanding the relationship and scaling Ensight’s footprint within the medical imaging sector.
The contract’s enterprise pricing reflects the scope of workflow functionality and study volume rather than merely site count, suggesting a tailored approach to value capture. The go-live is slated for the second half of 2026, with Enlitic poised to capitalise on growing real-world demand for AI-driven imaging workflow enhancements.
Bottom Line?
Enlitic’s first Australian subscription deal with Lumus sets a foundation for recurring SaaS growth but hinges on successful deployment and further enterprise wins.
Questions in the middle?
- How quickly will Enlitic convert this initial subscription into broader multi-site adoption within Lumus Imaging?
- Can Enlitic replicate this OEM channel success with Intelerad across other major imaging networks in the Asia-Pacific region?
- What impact will the shift to recurring SaaS revenue have on Enlitic’s overall financial profile in upcoming reporting periods?